Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Jun 4, 2026 · Filed Jun 5, 2026
The boss of Krystal Biotech sold $862K of Krystal Biotech shares. It happened by itself, for taxes or pay.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$861,620
Shares × reported transaction price
107 days after results of Feb 17, 2026, 60 days before results of Aug 3, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Filing box checked: sold under a Rule 10b5-1 plan
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +7.6% | +2.1% | +5.5% |
| 30 days | +24.4% | +0.8% | +23.6% |
| 90 days | +16.4% | +3.6% | +12.8% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Officer sold ~$347K of Krystal Biotech
Scheduled in advanceDerivative exercise or conversion — not an open-market buy.